TCON stock forecast
Our latest prediction for TRACON Pharmaceuticals, Inc.'s stock price was made on the Dec. 9, 2019 when the stock price was at 2.92$.
In the short term (2weeks), TCON's stock price should underperform the market by -7.08%. During that period the price should oscillate between -17.80% and +15.63%.
In the medium term (3months), TCON's stock price should underperform the market by -22.41%. During that period the price should oscillate between -48.50% and +33.89%.
Get email alertsAbout TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -8.80$ per share.
The book value per share is 1.24$
Three months stock forecastDec. 9, 2019
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3M | 100.00% | -26M | -208.00% | -26M | -8.80 | - | - | 3M | 1.24 | -28M | - | -28M |